首页 > 师资队伍 > 副教授副教授
靳艳丽
发布时间:2017-05-31

 

靳艳丽,女,医学博士,副研究员,硕士生导师。

2005年毕业于滨州医学院,获医学学士学位,2011年毕业于中山大学,获医学博士学位。2014年初来到暨南大学药学院工作。主要从事抗肿瘤药物药理学研究,在J Clin InvestCancer ResClin Cancer Res等重要专业杂志上已发表SCI论文25篇。获授权专利1项。获批主持国家自然科学基金面上项目2项。担任PLOS ONEAnti-Cancer DrugsBioorg Med Chem LettSCI期刊审稿人。广东省药理学会第二届肿瘤药理专业委员会委员。2012广东省优秀博士学位论文获得者。

 

研究方向:

1.肿瘤转移发生的分子机制及靶向药物干预

2.肿瘤干细胞的干性调控及靶向药物干预

 

研究工作经历:

2014.1-现在       副研究员,暨南大学药学院肿瘤药理学研究所

2011.11-2013.12    博士后,美国加州大学洛杉矶分校西奈医学中心(UCLA)

 

入选的人才项目:

1.广东省自然科学杰出青年基金  2016

2.广东省特支计划科技创新青年拔尖人才  2017

 

主持的科研课题:

1.国家自然科学基金面上项目 (批准号:81673451,主持)

2.国家自然科学基金面上项目 (批准号:81473247,主持)  

 

发表的代表性SCI论文:

1.Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J. Targeting PRMT5 confers elimination of chronic myelogenous leukemia stem cells in combination with imatinib. J Clin Invest. 2016;126(10):3961-3980. PMID: 27643437. (IF 12.575).

2.Jin Y, Nie D, Li J, Du X, Lu Y, Li Y, Liu C, Zhou J, Pan J. Gas6/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing β-catenin. Clin Cancer Res. 2016 Nov 16. [Epub ahead of print]. PMID: 27852702. (IF 8.738).

3.Jin Y, Yao Y, Chen L, Zhu X, Jin B, Shen Y, Li J, Du X, Lu Y, Jiang S, Pan J. Depletion of γ-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics. 2016;6(11):1947-62. PMID: 27570562. (IF 8.854).

4.Jin Y, Cao Q (共同第一作者), Chen C, Du X, Jin B, Pan J. Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells. BMC Cancer. 2015;15:226. (IF 3.265).

5.Jin Y, Han B, Chen J, Wiedemeyer R, Orsulic S, Bose S, Zhang X, Karlan BY, Giuliano AE, Cui Y, Cui X. FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. Ann Surg Oncol. 2014; 21 Suppl 4:758-66. PMID: 25124473. (IF 3.655).

6.Jin Y, Ding K, Wang D, Shen M, Pan J. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Cancer Lett. 2014;353(1):115-23. PMID: 25088577. (IF 5.992).

7.Jin Y, Ding K, Li H, Xue M, Shi X, Wang C, Pan J. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR: roles of Mcl-1 and -catenin. Mol Cancer. 2014;13(1):17. PMID: 24472312. (IF 5.888).

8.Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res. 2010; 70(6): 2516–27. PMID: 20215516. (IF 8.556).

9.Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010; 9(1):211-23. PMID: 20053766. (IF 5.579).

10.Jin Y, Chen Q, Shi X, Cheng C, Lu Z, Cheng C, Lai Y, Zheng Q, Pan J. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009; 100:1335-43. PMID: 19383029. (IF 3.896).

11.Jin Y, Chen Q, Lu Z, Chen B, Pan J. Triptolide abrogates oncogene FIP1L1-PDGFRα addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci. 2009; 100(11):2210-7. PMID: 19671059. (IF 3.896).

12.Shi X, Jin Y(共同第一作者), Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009; 15(5):1686-1697. PMID: 19240172. (IF 8.738).

13.Lu Z, Jin Y(共同第一作者), Chen C, Li J, Cao Q, Pan J. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl. Mol Cancer. 2010; 9(1):112. PMID: 20482842. (IF 5.888).

14.Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, Sakkiah S, Abrol R, Jensen TW, Berman BP, Tanaka H, Johnson J, Gao B, Hao J, Liu Z, Buttyan R, Ray PS, Hung MC, Giuliano AE, Cui X. FOXC1 activates smoothened-independent hedgehog signaling in basal-like breast cancer. Cell Rep. 2015;13(5):1046-58. PMID: 26565916. (IF 7.870).

15.Yu-Rice Y, Jin Y, Han B, Qu Y, Johnson J, Watanabe T, Cheng L, Deng N, Tanaka H, Gao B, Liu Z, Sun Z, Bose S, Giuliano AE, Cui X. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance. Oncogene. 2016;35(41):5400-5411. PMID: 27041579. (IF 7.932).